Provention Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRVB research report →
Companywww.proventionbio.com
Provention Bio, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.
- CEO
- Ashleigh W. Palmer
- IPO
- 2018
- Employees
- 174
- HQ
- Red Bank, NJ, US
Price Chart
Valuation
- Market Cap
- $2.38B
- P/E
- -16.44
- P/S
- 184.21
- P/B
- 15.32
- EV/EBITDA
- -18.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.03%
- Op Margin
- -993.88%
- Net Margin
- -880.69%
- ROE
- 133.43%
- ROIC
- -78.27%
Growth & Income
- Revenue
- $12.89M · 824.37%
- Net Income
- $-113,565,000 · 0.76%
- EPS
- $-1.52 · 16.02%
- Op Income
- $-128,161,000
- FCF YoY
- 20.91%
Performance & Tape
- 52W High
- $25.00
- 52W Low
- $3.19
- 50D MA
- $19.10
- 200D MA
- $10.15
- Beta
- 2.46
- Avg Volume
- 2.84M
Get TickerSpark's AI analysis on PRVB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 27, 23 | Sessa Capital (Master), L.P. | other | 15,567,497 |
| Apr 27, 23 | Wysenski Nancy | sell | 128,981 |
| Apr 27, 23 | Wysenski Nancy | sell | 22,200 |
| Apr 27, 23 | Wysenski Nancy | sell | 23,000 |
| Apr 27, 23 | Wysenski Nancy | sell | 33,000 |
| Apr 27, 23 | Pisano Wayne | sell | 33,000 |
| Apr 27, 23 | Pisano Wayne | sell | 23,000 |
| Apr 27, 23 | Pisano Wayne | sell | 24,000 |
| Apr 27, 23 | Pisano Wayne | sell | 128,981 |
| Apr 27, 23 | Pisano Wayne | sell | 22,200 |
Our PRVB Coverage
We haven't published any research on PRVB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRVB Report →